No headlines found.
Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial
Globe Newswire (Thu, 27-Jun 4:05 PM ET)
Acasti Announces Year-End 2024 Financial Results, Provides Business Update
Globe Newswire (Fri, 21-Jun 8:00 AM ET)
Acasti Pharma to Attend BIO International Convention 2024
Globe Newswire (Tue, 28-May 4:05 PM ET)
Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.
Acasti Pharma - Class A trades on the NASDAQ stock market under the symbol ACST.
As of July 26, 2024, ACST stock price declined to $2.76 with 10,800 million shares trading.
ACST has a market cap of $25.94 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ACST stock traded as high as $27.07 and as low as $1.72.
The top ETF exchange traded funds that ACST belongs to (by Net Assets): KRUZ.
ACST has underperformed the market in the last year with a price return of +7.8% while the SPY ETF gained +21.0%. ACST has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -5.8% and -8.9%, respectively, while the SPY returned +8.5% and -2.2%, respectively.
ACST support price is $2.69 and resistance is $2.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACST stock will trade within this expected range on the day.